食管癌淋巴结寡复发根治性挽救放疗与放化疗:日本237例多中心研究
日本五家医院237例食管癌淋巴结寡复发患者接受挽救性放疗(总剂量≥45 Gy),3年总生存率37%、局部控制率45%、无进展生存率24%、食管癌特异生存率42%。多因素分析显示联合化疗、无病间期≥12个月和淋巴结最大径≤22 mm与更好预后显著相关,提示长DFI和小淋巴结者经放化疗可能获得治愈。
要点
- 食管癌淋巴结寡复发接受挽救放疗后3年OS为37%,并非终末期事件。
- 联合化疗、DFI≥12个月、淋巴结最大径≤22 mm是多因素分析中显著预后因素。
- 长DFI且小淋巴结者经放化疗可能获得治愈。
核心结论
- 食管癌治疗后淋巴结寡复发并非终末期事件,长无病间期且淋巴结较小者经放化疗可能获得治愈。
研究设计与样本
- 日本五家医院多中心回顾性研究,纳入原发灶控制、1–5个淋巴结复发、无其他部位复发且挽救放疗总剂量≥45 Gy的237例患者。
- 挽救放疗时间为2000年1月至2015年4月,93例存活者中位随访29.6个月。
主要发现
- 237例患者3年总生存率37%,局部控制率45%,无进展生存率24%,食管癌特异生存率42%。
- 单因素分析中联合化疗(p=0.000055)、无病间期≥12个月(p=0.0013)、淋巴结最大径≤22 mm(p=0.0052)和KPS≥80%(p=0.030)与更好OS显著相关。
- 多因素分析中联合化疗(p=0.000018)、无病间期(p=0.0027)和淋巴结最大径(p=0.018)差异显著。
临床怎么用
- 对食管癌原发灶控制后的1–5个淋巴结寡复发、无其他部位复发者,可考虑根治性挽救放疗(总剂量≥45 Gy)联合化疗。
- 无病间期≥12个月和淋巴结最大径≤22 mm提示预后较好,可积极治疗以期治愈。
局限性
- 本研究为多中心回顾性分析,非前瞻性随机对照设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study evaluated the treatment results of lymph node (LN) oligo-recurrence in esophageal cancer patients treated with salvage radiotherapy (RT) in a multi-institutional retrospective study. METHODS: Eligibility criteria for this retrospective analysis were: the primary lesion of esophageal cancer was controlled; from one to five LN recurrences; total RT dose ≥45 Gy to exclude palliative RT; without recurrence other than LN; and salvage RT for LN recurrence was given between January 2000 and April 2015. The median follow-up time for the 93 living patients was 29.6 months. RESULTS: Two hundred thirty-seven patients were matched in five hospitals. The 3-year overall survival (OS) was 37%, local control was 45%, progression-free survival was 24%, and esophageal cancer-specific survival was 42%. On univariate analysis for OS, combined chemotherapy (p = 0.000055), disease-free interval (DFI) ≥12 months (p = 0.0013), LN max diameter ≤22 mm (p = 0.0052), and Karnofsky performance status ≥80% (p = 0.030) were associated with a significantly better prognosis. On multivariate analysis, significant differences were seen for combined chemotherapy (p = 0.000018), DFI (p = 0.0027), and LN max diameter (p = 0.018). CONCLUSIONS: LN oligo-recurrence following treatment for esophageal cancer was not a terminal-stage event. Moreover, cure may be possible by chemoradiation therapy with a long DFI (≥12 months) and small size (≤22 mm).
引用
- Yamashita H, Jingu K, Niibe Y, et al. Definitive salvage radiation therapy and chemoradiation therapy for lymph node oligo-recurrence of esophageal cancer: a Japanese multi-institutional study of 237 patients. Radiat Oncol. 2017. PMID: 28219406. doi:10.1186/s13014-017-0780-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。